Xvivo Perfusion ABXVIPF +1.65%90 Cash-to-Debt is 2.51 as of Mar. 2026, which is 86% below its 10-year median of 18.00. GuruFocus rates XVIPF with a GF Score™ of 90/100 and a GF Value™ of $41.76 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 848 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 55.31% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Xvivo Perfusion AB's cash to debt ratio for the quarter that ended in Mar. 2026 was 2.51.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Xvivo Perfusion ABcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Xvivo Perfusion AB's Cash-to-Debt or its related term are showing as below:
XVIPF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68 Med: 18 Max: No Debt
Current: 2.51
During the past 13 years, Xvivo Perfusion AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.68. And the median was 18.00.
XVIPF's Cash-to-Debt is ranked better than 55.31% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: 1.645
vs XVIPF: 2.51
Xvivo Perfusion AB (OTCPK:XVIPF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Xvivo Perfusion AB Cash-to-Debt Related Terms
Xvivo Perfusion AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Xvivo Perfusion AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Cash-to-Debt of 2.51 as of Mar. 2026. This is 86% below median its historical median of 18.00. Over the past decade, Xvivo Perfusion AB's Cash-to-Debt has ranged from 0.68 to 10,000.00. According to the industry distribution chart, Xvivo Perfusion AB ranks #379 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 44.7%.
Is Xvivo Perfusion AB's Cash-to-Debt too high?
Xvivo Perfusion AB's current Cash-to-Debt of 2.51 is 86% below median its 10-year median of 18.00. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.65. Xvivo Perfusion AB's value of 2.51 is 52.6% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #379 out of 848 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #379 out of 848 companies for Cash-to-Debt. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Cash-to-Debt is 1.65. Xvivo Perfusion AB's value of 2.51 is 52.6% above this benchmark. Historically, Xvivo Perfusion AB's own Cash-to-Debt has ranged from 0.68 to 10,000.00 over the past decade. While the company's 10-year median is 18.00 vs. the industry median of 1.65, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.65, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Cash-to-Debt of 2.51 is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Cash-to-Debt is 2.51, which is 86% below median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $41.76, compared to a current price of $29.48 — trading 29.4% below its estimated fair value. The current Cash-to-Debt is 2.51, which is 86% below median its 10-year median of 18.00 and 52.6% above the Medical Devices & Instruments industry median of 1.65. Xvivo Perfusion AB's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Cash-to-Debt is 2.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.48 is trading 29.4% below its estimated GF Value™ of $41.76.
GuruFocus considers Xvivo Perfusion AB to be Modestly Undervalued.
Key valuation signals for XVIPF:
Cash-to-Debt: 2.51 (86% below median its 10-year median of 18.00)
GF Value™: $41.76 vs. price of $29.48 (29.4% below fair value)
Industry Position: 52.6% above the Medical Devices & Instruments median (#379 of 848)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
90GF Score
Get the complete analysis for XVIPF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
